The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of ...

Teva Pharmaceutical (NYSE ... company's decision to rely heavily on U.S. generics via its $41B buyout of Actavis Generics in 2016. "Upon further reflection and dialogue with management, we believe ...

Teva has agreed to pay a whopping $1.2 billion to settle a US lawsuit claiming its subsidiary Cephalon paid to hold up generic competition ... subsidiary Solvay and Actavis unit Watson on ...

With more than five dozen generics already tentatively approved for 10 of the drugs selected for the next round of the Medicare Price Negotiation Program, the impact of the negotiations won’t be ...

He acknowledged that Teva is still facing significant challenges, not least of which is a high level of debt that accompanied its takeover in 2017 of generic drugmaker Actavis, albeit reduced from ...

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.

Gujarat-based drugmaker Intas Pharmaceuticals Ltd., which counts private ... the company made bold moves overseas as it acquired Actavis’ UK and Actavis Ireland businesses from Teva Pharmaceutical ...